Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2018-06-11 Major Shareholding Noti…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 99% confidence The document explicitly details changes in shareholding percentages and the number of underlying shares held by 'NEXTTOBE AB' in 'Hansa Biopharma AB'. Key phrases like 'Reason for major shareholding notification', 'Resulting distribution of total holdings', and the reporting of percentages crossing thresholds (e.g., 20% threshold mentioned, final holding at 17.53983%) strongly indicate a notification regarding a significant change in ownership. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2018-06-11 English
Presentation vid 2018 American Transplant Congress visar den långsiktiga risk/nytta-profilen för imlifidase (IdeS) vid njurtransplantation
Regulatory Filings Classification · 99% confidence The document is a press release dated June 6, 2018, announcing the presentation of supplementary data and conclusions from a Phase II study of imlifidase (IdeS) at the 2018 American Transplant Congress (ATC). It details clinical results (patient survival, AMR rates, DSA levels) and includes quotes from a presenting professor and mentions other presentations/posters at the conference. It concludes with standard boilerplate information about the drug, the company, and a statement that the information is disclosed under EU Market Abuse Regulation. This content structure—announcing clinical data presented at a specific medical conference—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS) if it were purely informational. However, since it is a detailed announcement of clinical trial results and scientific findings, it functions as a key update for investors regarding product development progress. Given the options, it is not a full Annual Report (10-K), an Interim Report (IR), or a formal Investor Presentation (IP). It is a press release detailing scientific/clinical progress, which often overlaps with ER, but since it is focused on scientific data presentation rather than quarterly financial performance highlights, and it is a formal disclosure, 'Regulatory Filings' (RNS) is the most appropriate general category for non-standard, material announcements, or 'Earnings Release' (ER) if it were tied to a reporting period. Since it is a specific scientific update announcement, and not a standard financial earnings release, RNS is a strong candidate. However, many companies use press releases to announce significant clinical data updates, which are material non-public information. Given the context of a biopharma company announcing study results presented at a major congress, this is a critical investor update. If we must choose the most specific fit among the provided options for a press release announcing scientific/clinical progress, and it is not explicitly an ER, IR, or IP, RNS serves as the best fit for a general regulatory announcement of material information not covered by other specific codes. Upon re-evaluation, this document is a detailed announcement of clinical trial results presented at a conference, which is a form of material information disclosure. It is not a standard ER (which focuses on financial metrics). It is not a CT, IP, or MDA. It is a formal disclosure of scientific progress. RNS is the best fit as a general regulatory announcement.
2018-06-06 Swedish
Presentation at the 2018 American Transplant Congress highlights the long-term risk-benefit profile of imlifidase (IdeS) in kidney transplantation
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE" dated June 6, 2018. It announces the presentation of new data and conclusions from a clinical study (Phase II with imlifidase) at the 2018 American Transplant Congress (ATC). It summarizes key findings (renal function, AMR rates, survival probabilities) and includes quotes from the presenting professor and company personnel. This format—a brief announcement summarizing recent scientific or operational news, often referencing a presentation or publication—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management discussion (MDA), and it is a direct announcement of results/data presentation, it fits best as an Earnings Release (ER) if the data release is tied to a reporting period, or RNS if it's purely scientific/regulatory news. Given the context of presenting clinical data and the structure of a press release, it functions as an announcement of key operational/scientific progress, which often overlaps with ERs or is captured by RNS. However, since it is a press release announcing scientific data rather than quarterly financial figures, and it is not a short notice about a report being available (RPA), the most appropriate general category for significant, non-standard regulatory news is RNS, or ER if the data release is considered the primary periodic update. Given the focus on clinical trial results and presentation at a conference, RNS (Regulatory Filings/General Announcement) is a strong fit, but ER (Earnings Release) often encompasses major operational updates presented to the market. Since it is a press release announcing data, and not a formal financial statement, RNS is the safest general classification for non-standard announcements. I will classify it as RNS as it is a general regulatory announcement via press release about clinical data, not a formal financial report or a specific management discussion.
2018-06-06 English
Long-term follow up data from investigator-initiated Phase II study with imlifidase (IdeS) to be presented at 2018 American Transplant Congress (ATC)
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE" dated May 30, 2018. It announces that long-term follow-up data from a clinical study will be presented at an upcoming conference (2018 American Transplant Congress). It summarizes key findings (renal function, AMR rates) and mentions that an abstract is available. Crucially, it states: "This is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation." This structure—a brief announcement summarizing results that will be detailed elsewhere (abstract/presentation)—is characteristic of an Earnings Release (ER) or a general Regulatory Announcement. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a formal announcement of results/data presentation mandated by regulation, the best fit among the options is Earnings Release (ER), as it releases key performance/study results. It is not a Report Publication Announcement (RPA) because it is releasing the *content* of the findings, not just announcing the *publication* of a separate, attached report.
2018-05-30 English
Uppföljningsresultat från prövarinitierad fas II-studie med imlifidase (IdeS) kommer att presenteras vid 2018 American Transplant Congress (ATC)
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE" dated May 30, 2018. It announces that follow-up results from a clinical trial (imlifidase study) will be presented at an upcoming conference (2018 American Transplant Congress - ATC). It summarizes key findings, mentions previous publication in NEJM, and includes standard regulatory disclosure language ("This information is such that Hansa Medical AB is required to make public pursuant to the EU Market Abuse Regulation"). This structure—a brief announcement about the release or presentation of data/results, rather than the full financial report itself (like 10-K or IR)—strongly suggests it is an announcement regarding corporate or clinical updates. Since it is not a formal financial report, a management discussion, or a specific regulatory filing like DIRS or DIV, the most appropriate classification is a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the context implied quarterly results, but here it is specifically about a clinical data presentation. Given the nature of announcing clinical data presentation and the press release format, RNS (Regulatory Filings/General Announcement) is the best fit, as it is a general corporate disclosure not covered by the more specific financial/governance codes. It is not short enough to definitively trigger the RPA rule, but it is an announcement of future presentation, making RNS the safest general category for non-financial, non-insider corporate news.
2018-05-30 Swedish
Kommuniké från årsstämma i Hansa Medical AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Kommuniké från årsstämma i Hansa Medical AB (publ)" (Communiqué from the Annual General Meeting of Hansa Medical AB (publ)). It details the decisions made during the meeting, such as the approval of financial statements, election/re-election of board members and auditors, determination of remuneration, approval of incentive programs, and principles for the nomination committee. These contents are characteristic of the official minutes or a summary release following an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2018-05-29 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.